An oral GLP-1 receptor agonist lowered HbA1c and body weight in phase 2 but was halted early after transaminase elevations ended its development. PICO summary and expert commentary.
Browsing: Diabetes
Evidence summaries and landmark trials across type 1, type 2, prevention, glycaemic control, complications, and diabetes technology.
Two small crossover trials in adults with type 1 diabetes found neither protein source nor carbohydrate glycaemic index significantly altered postprandial glucose. PICO summary and expert commentary.
A 253-adult randomized trial found that 25% calorie restriction produced consistent enteropancreatic hormone shifts across diet patterns, and that larger shifts were associated with more weight regain afterwards. PICO summary and expert commentary.
A manufacturer-sponsored randomized trial of a low-glycemic-index/slow-digesting carbohydrate product in obese pregnant women found no effect on the primary glycemic outcomes. PICO summary and expert commentary.
A post-hoc EXSCEL analysis testing whether baseline ejection fraction modifies the effect of once-weekly exenatide on heart failure hospitalisation in type 2 diabetes. PICO summary and expert commentary.
A Sanofi-sponsored post hoc analysis of the LixiLan-L-CN trial reports that iGlarLixi lowered residual hyperglycaemia more than insulin glargine alone in Chinese adults with type 2 diabetes. PICO summary and expert commentary.
Exploratory analysis of AMPLITUDE-O finds baseline FIB-4 score is not associated with cardiovascular outcomes and does not modify efpeglenatide’s effect in high-risk type 2 diabetes. PICO summary and expert commentary.
The ARIADNE non-inferiority trial tested whether a supported total diet replacement programme worsened eating disorder symptoms in adults with type 2 diabetes at high risk. PICO summary and expert commentary.
A Phase 2 randomised trial in 145 adults found once-weekly ecnoglutide lowered HbA1c by up to 2.39% versus 0.55% with placebo over 20 weeks. PICO summary and expert commentary.
A double-blind RCT testing whether the Omentin-1 Val109Asp genotype modifies vitamin D’s effects on HDL-C, insulin resistance and abdominal obesity in prediabetic women. PICO summary and expert commentary.